A new Covid vaccine soon to be marketed? This is what French-Austrian laboratory Valneva wishes as they announced they have launched the production of their candidate vaccine, as clinical trials are still on going. The goal? As the biotech explains in a release, “to optimize timeline for potential deliveries” of the product, already requested by the United-Kingdom that order back in September 60 million doses. A vaccine also ordered by the European Union including exploratory negotiations secured for 60 million doses as well.
Clinical trials are still going on and they are coming along nicely. As phases 1 and 2 results of the study - released this Tuesday April 6 - have delivered conclusive results, with over 90% of volunteers developing a high concentration of antibodies, the laboratory is waiting for approval from the British bodies who ordred the vaccine, to start the third and last phase of the clinical trial, by the end of the month.
The vaccine relies on the “inactivated virus” technology, the standard form of vaccines so far, like products developed by Sinovac and Sinopharm. As for the clinical trials, currently completing phase 2, they include 150 adults. Too little to draw definitive conclusions, but enough to hope and make it to the end of research process. A vaccine that – if results are met – is expected to be issued by the end of 2021.
For the record, two vaccines are currently marketed in Europe: Pfizer/BioNTech and Moderna Therapeutics. Two others are waiting to be approved by the European Medicines Agency, namely AstraZeneca – expected to be approved by the end of January – and Sputnik V, developed in Russia. Other vaccines are also being studied in French laboratories such as Institut Pasteur’s expected to be issued by the end of 2021 and Ose Immunotherapeutics – currently being developed.